Showing results (261-270 of 356) with videos related to
Sort By:
Pageof 36
Nature Neuroscience|June 13, 2017
A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastomaGao Guo, Ke Gong, Sonia Ali, et al.Scientific Reports|November 17, 2021
A phase I study of the WT2725 dosing emulsion in patients with advanced malignanciesSiqing Fu, David E Piccioni, Hongtao Liu, et al.Oncotarget|March 19, 2015
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancerDavid M Jackman, Leigh A Cioffredi, Lorraine Jacobs, et al.Scientific Reports|May 21, 2020
IRE1α and IGF signaling predict resistance to an endoplasmic reticulum stress-inducing drug in glioblastoma cellsJeffrey J Rodvold, Su Xian, Julia Nussbacher, et al.Journal of Neuro-Oncology|January 20, 2011
Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomasDeviney Chaponis, Jessica W Barnes, Jamie L Dellagatta, et al.Frontiers in Oncology|August 18, 2016
Demonstration of Non-Gaussian Restricted Diffusion in Tumor Cells Using Diffusion Time-Dependent Diffusion-Weighted Magnetic Resonance Imaging ContrastTuva R Hope, Nathan S White, Joshua Kuperman, et al.Molecular Cancer Therapeutics|February 14, 2016
Precision Oncology: The UC San Diego Moores Cancer Center PREDICT ExperienceMaria Schwaederle, Barbara A Parker, Richard B Schwab, et al.Journal of Translational Medicine|January 18, 2014
Novel anti-glioblastoma agents and therapeutic combinations identified from a collection of FDA approved drugsPengfei Jiang, Rajesh Mukthavaram, Rajesh Mukthavavam, et al.Journal of Neurosurgery|August 28, 2012
Prognosis of patients with multifocal glioblastoma: a case-control studyChirag G Patil, Anthony Yi, Adam Elramsisy, et al.Plos One|April 6, 2012
Loss of PTEN is not associated with poor survival in newly diagnosed glioblastoma patients of the temozolomide eraChristine Carico, Miriam Nuño, Debraj Mukherjee, et al.Pageof 36